12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Wednesday's pre-market session, several healthcare stocks showed significant movement. Vivos Therapeutics (VVOS) saw a substantial increase of 132.6%, while Avenue Therapeutics (ATXI) and Redhill Biopharma (RDHL) also experienced notable gains. Conversely, Eagle Pharmaceuticals (EGRX) and Heart Test Laboratories (HSCS) were among the stocks that declined. Patterson Cos (PDCO) reported Q2 earnings, which may have influenced its stock decrease.
November 29, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eagle Pharmaceuticals shares decreased by 14.3% to $7.05, with a market value of $91.5 million.
The pre-market decline in EGRX shares could be a negative signal to investors, potentially leading to a short-term downtrend in the stock price.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Heart Test Laboratories shares fell 13.01% to $0.23, with a market cap of $11.2 million.
The drop in HSCS shares may concern investors, potentially causing a short-term negative effect on the stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Patterson Cos stock decreased by 9.33% to $28.5 post-Q2 earnings, with a market cap of $2.7 billion.
The decline in PDCO stock following the Q2 earnings release suggests the market's reaction may be negative, which could lead to a short-term decrease in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Avenue Therapeutics shares increased by 59.99% to $0.3, with a market cap of $7.6 million.
The sharp rise in ATXI shares suggests positive investor sentiment, which could result in a short-term uptrend for the stock.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Redhill Biopharma stock increased by 31.14% to $2.99, with a market cap of $33.1 million.
Redhill Biopharma's pre-market gain could attract investor attention, potentially leading to a short-term positive impact on the stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Vivos Therapeutics shares soared by 132.6% to $10.21, with a market cap of $12.2 million.
The significant pre-market surge in VVOS shares indicates strong investor interest, likely due to positive news or expectations, which could lead to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100